Abstract: In a production method for a conductive composite material for an extruder that continuously discharges a kneaded product produced by kneading a raw material using a screw, the screw has a the screw body, the raw material transported along an outer circumferential surface of the screw body receives increased pressure by a barrier part in a transport part and is introduced to a passage from an inlet, and while the kneaded product is continuously discharged, the raw material transported along the outer circumferential surface of the screw body flows in the passage of the extruder and then is guided to the transport part via an outlet provided in the screw body, the raw material contains a conductive filler and a thermoplastic elastomer.

Abstract: A kneading apparatus includes a processor, and a extruder. The extruder includes a screw. The screw includes a screw main body. A conveyance portion, a barrier portion, and a path are provided at places of the screw main body. In at least one of the places, the path is provided inside the screw main body, and includes an entrance and an exit. The raw materials, pressure on which is increased by the barrier portion, flow in from the entrance. The raw materials flowing in from the entrance flow through the path toward the exit. The exit is positioned to be remote from the entrance in an axial direction.

Abstract: A lift carrier (10) includes: a carrier frame that is inserted under a vehicle to be transported; a lifting mechanism that lifts and lowers the carrier frame to lift and lower the vehicle; and a carrier body configured to move the carrier frame. The carrier frame includes a rear end frame that includes a pair of arm fixing plates provided so as to protrude outward in a lateral direction of the vehicle from lower surfaces of the side members. The top plate is fixed to the rear end frame, fixes a plurality of rear end arms at such positions that the rear end arms are sandwiched between the top plate and the arm fixing plates, and fixes an upper end face of a lifting unit that is the lifting mechanism.

Abstract: A lift carrier includes: a bogie frame that is inserted under a transport target vehicle; an elevating mechanism that raises and lowers the bogie frame with each of a plurality of tires supported with arms to raise and lower a vehicle; a bogie body that is able to move the bogie frame to any location. The bogie frame includes a main frame and a rear end frame joined to the main frame. The rear end frame is formed in a rectangular shape by a pair of side members, a first cross member, and a second cross member. The rear end frame includes a first reinforcing member projecting from the first cross member toward a front end side and a second reinforcing member projecting from the first cross member toward a rear end side. The first reinforcing member is joined to a part of the main frame.

Abstract: A carrier body of a lift carrier includes: a pair of wheel support mechanisms that supports a first wheel of a vehicle to be transported; a frame-shaped structure connected to the wheel support mechanisms; and one or more lifting units that lift or lower the pair of wheel support mechanisms. The frame-shaped structure includes a frame portion and an upper plate and is open on a lower side of the carrier body. Each of the lifting units includes a wheel support and an air spring. The air spring is interposed between the wheel support and an upper plate. As the air spring expands, the wheel support is rotated about one end of the wheel support rotatably supported by the frame portion, and is deployed out of the frame-shaped structure.

Abstract: A vehicle transporting device includes a bogie frame, a device main body, and an upright frame. The upright frame connects a tip portion of the bogie frame and the device main body. The bogie frame includes two frame members and at least two pipes, which are disposed parallel to a longitudinal direction of the bogie frame. The two frame members are disposed parallel to the at least two pipes at a position outside the at least two pipes in a width direction of the bogie frame. The at least two pipes include two pipes facing each other in the width direction. A reinforcing member extending in the width direction is provided at the tip portion of the bogie frame and between the two facing pipes. The two frame members, the reinforcing member, and the upright frame are connected to each other at the tip portion of the bogie frame.

Abstract: A vehicle conveyor includes a slide member that is provided on each of opposite side faces of a carriage portion, and slides along a longitudinal direction of the carriage portion, independently of the carriage portion. A first arm set and first arm actuators are joined to the slide members, and are configured to slide along the longitudinal direction of the carriage portion, integrally with the slide members, independently of the carriage portion.

Abstract: An extruder screw includes a screw body. The screw body is rotated about an axis parallel to a direction of conveyance of a raw material. A conveyance portion having a flight is provided on the outer peripheral surface of the screw body. The flight is configured to convey the raw material along the axis of the screw body when the screw body is rotated. A passage for permitting the raw material fed by the flight to pass therethrough to the outer peripheral surface of the screw body is provided in the screw body in a position deviated from the axis of the screw body.

Abstract: The present invention provides a lubricating oil composition not containing ZnDTP but comprising: (a) a base oil; (b) molybdenum dialkyldithiocarbamate; and (c) an organic acid metal salt compound having a metal of Group 8 of a short periodic table, copper, or bismuth as a central metal.

Abstract: The present invention provides a lubricating oil composition not containing ZnDTP but comprising: (a) a base oil; (b) molybdenum dialkyldithiocarbamate; and (c) an organic acid metal salt compound having a metal of Group 8 of a short periodic table, copper, or bismuth as a central metal.

Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

Abstract: To provide a compound which can be used as an MC4 receptor agonist. The present inventors have investigated MC4 receptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.

Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

Abstract: [Problem] To provide a compound which can be used as an MC4 receptor agonist. [Means for Solution] The present inventors have investigated MC4 receptor agonists, and have found that a piperazine derivative has an action related to the agonists, thereby completing the present invention. That is, the piperazine derivative of the present invention has an MC4 receptor agonistic action, and can be used as an agent for preventing or treating bladder and/or urinary tract diseases, in particular, underactive bladder, hypotonic bladder, acontractile bladder, detrusor underactivity, neurogenic bladder, urethral relaxation failure, detrusor-external urethral sphincter dyssynergia, and voiding dysfunctions in benign prostatic hyperplasia.

Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

Abstract: [Problem] To provide a compound useful as a MT1 and/or MT2 receptor agonist. [Solution] The present inventors have studied on MT1 and/or MT2 receptor agonists, and have confirmed that indole compounds have the activity. As a result, the present invention is accomplished. That is, a compound represented by formula (I) or a salt thereof according to the present invention has a MT1 and/or MT2 receptor agonistic activity and has a low ability of migrating into central nervous system. Therefore, the compound or a salt thereof can be used as a peripheral MT1 and/or MT2 receptor agonist, and therefore can be used as a therapeutic and/or prophylactic agent for urinary incontinence, particularly stress urinary incontinence and mixed urinary incontinence.

Abstract: Provided is a compound which is useful as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT2C receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT2C receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT2C receptor agonist activity and can be used as an agent for treating or preventing 5-HT2C receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

Abstract: To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (IBS). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (BB2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is highly effective on bowel movement disorders. From the above, the tetrahydroisoquinolin-1-one derivative of the present invention is useful as a therapeutic agent for diseases associated with a BB2 receptor, in particular IBS.

Abstract: [Problem] To provide a compound useful as a MT1 and/or MT2 receptor agonist. [Solution] The present inventors have studied on MT1 and/or MT2 receptor agonists, and have confirmed that indole compounds have the activity. As a result, the present invention is accomplished. That is, a compound represented by formula (I) or a salt thereof according to the present invention has a MT1 and/or MT2 receptor agonistic activity and has a low ability of migrating into central nervous system. Therefore, the compound or a salt thereof can be used as a peripheral MT1 and/or MT2 receptor agonist, and therefore can be used as a therapeutic and/or prophylactic agent for urinary incontinence, particularly stress urinary incontinence and mixed urinary incontinence.